ScoreWhy is Monte Rosa Therapeutics, Inc. ?
1
The company has declared Positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 27.72 MM
- NET SALES(Q) At USD 23.19 MM has Grown at 394.01%
- ROCE(HY) Highest at 9.81%
2
With ROE of 2.24%, it has a expensive valuation with a 1.12 Price to Book Value
- Over the past year, while the stock has generated a return of 89.36%, its profits have risen by 104.6% ; the PEG ratio of the company is 0.5
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 89.36% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Monte Rosa Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Monte Rosa Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Monte Rosa Therapeutics, Inc.
75.05%
3.32
89.99%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
181.95%
EBIT Growth (5y)
31.69%
EBIT to Interest (avg)
-82.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.28
Tax Ratio
34.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.56%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
50
Industry P/E
Price to Book Value
1.12
EV to EBIT
6.60
EV to EBITDA
-2.29
EV to Capital Employed
0.30
EV to Sales
-0.09
PEG Ratio
0.48
Dividend Yield
NA
ROCE (Latest)
4.53%
ROE (Latest)
2.24%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend31What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 27.72 MM
NET SALES(Q)
At USD 23.19 MM has Grown at 394.01%
ROCE(HY)
Highest at 9.81%
RAW MATERIAL COST(Y)
Fallen by -62.99% (YoY
PRE-TAX PROFIT(Q)
At USD -11.1 MM has Grown at 63.08%
NET PROFIT(Q)
At USD -12.29 MM has Grown at 59.44%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Monte Rosa Therapeutics, Inc.
Net Sales
At USD 23.19 MM has Grown at 394.01%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 27.72 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -11.1 MM has Grown at 63.08%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -12.29 MM has Grown at 59.44%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -62.99% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 2.12 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
